Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872266 | 0.83 | EPHX1 (0.43) | EPHX1ATMMAPK1MTNR1AMTNR1B | |
| SCHEMBL10710177 | 0.83 | EPHX1 (0.43) | EPHX1MEN1KMT2AATMMAPK1 | |
| SCHEMBL19658638 | 0.81 | MEN1 (0.41) | EPHX1MEN1KMT2ACYP2C9MTNR1A | |
| SCHEMBL10314187 | 0.80 | EPHX1 (0.46) | EPHX1MEN1KMT2AATMMAPK1 | |
| SCHEMBL10008936 | 0.80 | CYP2D6 (0.50) | EPHX1MEN1KMT2AATMMAPK1 | |
| SCHEMBL12969433 | 0.80 | MEN1 (0.44) | MEN1KMT2AMAPK1SMN1; SMN2CYP2C9 | |
| SCHEMBL2354778 | 0.79 | EPHX1 (0.40) | EPHX1MEN1KMT2AATMMAPK1 | |
| SCHEMBL11779858 | 0.78 | EPHX1 (0.45) | EPHX1MEN1KMT2AATMMAPK1 | |
| SCHEMBL6727234 | 0.77 | FAAH (0.56) | MEN1KMT2AMAPK1CYP2C9 | |
| SCHEMBL10623417 | 0.77 | EPHX1 (0.44) | EPHX1MEN1KMT2AATMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105873932-B | (6S,9aS) -N-benzyl-6- [ (4-hydroxyphenyl) methyl ] -4, 7-dioxo-8- ({6- [3- (piperazin-1-yl) azetidin-1-yl ] pyridin-2-yl } methyl) -2- (prop-2-en-1-yl) -octahydro-1H-pyrazino [2,1-c ] [1,2,4] triazine-1-carboxamide compound | 卫材R&D管理有限公司 | 2017-11-24 | — | — | CN | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | PRISM BIOLAB CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | EPHX1 1652/4885MEN1 2962/4885KMT2A 1322/4885 |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | EPHX1 1652/4885MEN1 2962/4885KMT2A 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.